*Internal Medicine Article of the Day!* Just released in @NatureMedicine: *Large Cohort Study on GLP-1 Receptor Agonists* 🩺📊 Why it matters: *A real-world look at benefits vs. risks in T2DM*. 🔑 Key Findings: ✅ *Cardiac arrest ↓22%* (HR 0.78), *HF ↓11%* (HR 0.89) 🧠 Neuro benefits: *Alzheimer’s ↓12%, suicidal ideation ↓10%* 💔 *Coagulopathy and clotting disorders ↓8%, acute kidney injury ↓12%* ⚠️ Risks: *Drug-induced pancreatitis ↑146% 😮, nephrolithiasis ↑15%, arthritis ↑11%* 📊 Study Design: - n=215,970 GLP-1RA users vs. 1.9M controls - 3.68 yrs median follow-up, propensity-score weighted ⚠️ Caveats: - Mostly older male (VA data) - *Observational design → residual confounding* 🔗 Full article: https://www.nature.com/articles/s41591-024-03412-w 🔗 Summary on LM: https://www.linksmedicus.com/news/observational-cohort-study-glp-1-receptor-agonists-demonstrate-wide-ranging-benefits-but-elevate-gastrointestinal-renal-and-musculoskeletal-risks/